Which of the following is NOT a component of the cancer registry's quality control policy?

• A. Annual data review
• B. Patient follow-up
• C. Case validation
• D. Random auditing

Answer: (B)

Patient follow-up is not typically considered a direct component of a cancer registry's quality control policy. Instead, the quality control measures primarily focus on ensuring the accuracy, completeness, and reliability of the data collected.

Annual data reviews, case validation, and random auditing are all integral components of quality control in a cancer registry. These activities help to assess the accuracy of the registry's data and identify any potential discrepancies or areas for improvement. Annual data reviews involve systematic evaluations of the data collected over the year, case validation ensures that each reported case meets the necessary criteria for inclusion in the registry, and random auditing serves to verify the consistency and accuracy of the data by checking selected entries against source documents.

In contrast, patient follow-up is more related to post-treatment patient tracking and ensuring that outcomes are recorded, rather than directly addressing the quality of the data that is already in the registry. This distinction clarifies why patient follow-up is not categorized as a component of the quality control policy for a cancer registry.